BIOMAT Database Logo BIOMAT Database Logo

Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease. 2012

Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404, USA. Michael.Clarke@gilead.com

A novel, potent, and orally bioavailable class of product-like inhibitors of the HCV NS3 protease was discovered by constraining the P2-P3 amide bond and the P3 hydrocarbon substituent to the protease-bound conformation. This preorganization was accomplished by incorporation of the P2-P3 amide into a six-membered ring attached to the P2-proline 5-position. Isothermal calorimetric characterization of the role of hydrocarbon substitution of this six-membered ring, upon binding the HCV NS3 protease, was found to be exclusively entropic in nature. The synthesis, preliminary SAR and pharmacokinetic profiling of this compact, indolizidinone-derived scaffold are described.

UI MeSH Term Description Entries
D007212 Indolizines
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017361 Viral Nonstructural Proteins Proteins encoded by a VIRAL GENOME that are not structural components of VIRUS PARTICLES. Some of these proteins may play roles within the infected cell during VIRUS REPLICATION or act in regulation of virus replication or VIRUS ASSEMBLY. Nonstructural Proteins, Viral,NS Proteins, Viral,Viral NS Proteins,Viral Non-Structural Proteins,Viral Nonstructural Protein,Viral Nonstructural Proteins NS1,Viral Nonstructural Proteins NS2,Nonstructural Protein, Viral,Viral Non Structural Proteins
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
June 2011, Bioorganic & medicinal chemistry letters,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
February 2006, Journal of medicinal chemistry,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain.
December 2020, Journal of molecular graphics & modelling,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
August 2006, Bioorganic & medicinal chemistry,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
March 2006, Antimicrobial agents and chemotherapy,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
September 2008, Bioorganic & medicinal chemistry letters,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease.
February 2014, Bioorganic & medicinal chemistry letters,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
February 2009, Bioorganic & medicinal chemistry letters,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Hepatitis C Virus NS3/4A Protease Inhibitors.
November 2008, Recent patents on anti-infective drug discovery,
Michael O Clarke, and Daniel Byun, and Xiaowu Chen, and Edward Doerffler, and Stephanie A Leavitt, and X Christopher Sheng, and Cheng Y Yang, and Choung U Kim
Hepatitis C virus NS3/4a protease inhibitors.
October 2016, Current opinion in pharmacology,
Copied contents to your clipboard!